Nicergoline is a semi-synthetic ergoline derivative that plays as α-blocker and can strengthen vascular systems, brain cell metabolism, oxygen and glucose digestion and dopamine conversion so that nerve conduction and brain function can be improved. Nicergoline was originally developed by Pfizer. It can be applied to a wide range of symptoms, so it became popular worldwide since its launch.
According to CRI’s analysis, due to the expired patent of nicergoline in China, the market has been dominated by generic drugs. At present, there are many companies that produce nicergoline. Among them, Kunshan Rotam Reddy Pharmaceutical Co., Ltd. occupies a major share. Its market share exceeded 60% in 2017, and other manufacturers with high market occupancy include Pfizer, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. and China Meheco Sanyang Pharma Co., Ltd. etc. In China, dosage forms of nicergoline include freeze-dried powder injections, capsules, tablets and injections. Manufacturers of tablets are in a great number. The main manufacturer of injections is Hainan General Kangli Pharmaceutical Co., Ltd., and the major manufacturers of capsules are Fuan Pharmaceuticals and China Meheco Sanyang Pharma Co., Ltd. etc.
According to CRI’s analysis, nicergoline has been on the market for more than 40 years. Its market size and market share in anti-Alzheimer’s drugs is not large due to the fierce competition. Its product life cycle has entered a maturity stage. In 2017, the sales value of nicergoline was approximately CNY 129 million, with a slight increase over 2016.
It is expected that from 2018 to 2022, due to competition from other types of anti-Alzheimer’s drugs such as biopharmaceuticals, the market size of nicergoline will not grow rapidly but will remain flat or grow at a low rate. However, due to the lower average price, nicergoline is still active in the Chinese market. The sales of nicergoline will not drop significantly during 2018 to 2022 and will not be replaced by other drugs either.